Group 1 - The company received the approval notice for the supplementary application of Propranolol Hydrochloride Tablets, indicating that the product has passed the consistency evaluation of generic drug quality and efficacy [1][2] - Propranolol Hydrochloride Tablets were first launched in Japan in October 1966 under the brand name Inderal, with a specification of 10mg [2] - The indications for the drug include secondary prevention of myocardial infarction mortality, hypertension treatment, control of various types of arrhythmias, and management of hyperthyroidism-related tachycardia [2] Group 2 - In 2023, the domestic sales amount of Propranolol Hydrochloride Tablets was approximately 82.18 million RMB, with public medical market sales accounting for about 57.76 million RMB and retail pharmacy sales around 24.42 million RMB [2] - As of the announcement date, six other companies in China have also passed the consistency evaluation for this drug [2] - The company has invested approximately 2.6 million RMB in the research and development of this project [2]

Core Viewpoint - The announcement indicates that the company's subsidiary, Taiyuan Pharmaceutical, has received approval from the National Medical Products Administration for the supplement application of Propranolol Hydrochloride Tablets, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - The approved drug, Propranolol Hydrochloride Tablets, is expected to contribute to the company's revenue, as the domestic sales amount for this drug in 2023 is approximately 82.18 million RMB [1] - The public medical market accounts for about 57.76 million RMB of the total sales, while retail pharmacies contribute approximately 24.42 million RMB [1] - Currently, six other companies have also passed the consistency evaluation for this drug in the domestic market [1] Group 2: R&D Investment - The company has invested approximately 2.6005 million RMB in the research and development of this product [1]